Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

被引：33
|
作者：
Kosmider, Olivier [1 ]
Passet, Marie [1 ]
Santini, Valeria [2 ]
Platzbecker, Uwe [3 ]
Andrieu, Valerie [4 ]
Zini, Gina [5 ]
Beyne-Rauzy, Odile [6 ]
Guerci, Agnes [7 ]
Masala, Erico [8 ]
Balleari, Enrico [9 ]
Bulycheva, Ekaterina [3 ]
Dreyfus, Francois [10 ]
Fenaux, Pierre [11 ]
Fontenay, Michaela [1 ]
Park, Sophie [12 ]
机构：
[1] Hop Cochin, AP HP, Hematol Biol, Paris, France
[2] Univ Florence, AOU Careggi, Hematol, I-50121 Florence, Italy
[3] Univ Hosp Carl Gustav Dresden, Dresden, Germany
[4] Hop Bichat Claude Bernard, AP HP, Hematol Biol, Paris, France
[5] Univ Cattolica Sacro Cuore, Rome, Italy
[6] Oncopole, IUCT, Toulouse, France
[7] Hop Brabois, Nancy, France
[8] Univ Florence, Florence, Italy
[9] IRCCS AOU San Martino IST Genova, Genoa, Italy
[10] Hop Cochin, Serv Hematol, Paris, France
[11] Hop St Louis, Serv Hematol Seniors, Paris, France
[12] Univ Grenoble Alpes, CHU Grenoble Alpes, Clin Univ Hematol, Grenoble, France
来源：
HAEMATOLOGICA | 2016年 / 101卷 / 07期
关键词：
myelodysplastic syndromes; cytogenetics and molecular genetics; red cells; SURVIVAL; IMPACT; MODEL;
D O I：
10.3324/haematol.2016.142695
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：280 / 283
页数：4
相关论文
共 50 条
  • [21] Clinical Outcomes and Healthcare Resource Utilization for Patients With Lower-Risk Myelodysplastic Syndromes Treated With Erythropoiesis-Stimulating Agents
    Garcia-Manero, Guillermo
    Matsuno, Rayna K.
    McBride, Ali
    Mohammed, Hina
    Idryo, Danny
    Broome, Ronda
    Herriman, Autumn
    Johnson, Tiffany
    Wilkinson, Kristiana
    Schrag, Andrew
    Johanson, Colden
    Izano, Monika
    Makinde, Adeola
    Mukherjee, Sudipto
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (09): : e283 - e292
  • [22] Impact of Somatic Gene Mutations on Response to Lenalidomide (LEN) in IPSS Lower-Risk Myelodysplastic Syndromes (MDS) Patients (Pts) without Del(5q) and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents (ESAs)
    Santini, Valeria
    Fenaux, Pierre
    Giagounidis, Aristoteles
    Platzbecker, Uwe
    List, Alan F.
    Zhong, Jianhua
    Wu, Chengqing
    Mavrommatis, Konstantinos
    Beach, C. L.
    Hoenekopp, Albert
    MacBeth, Kyle J.
    BLOOD, 2016, 128 (22)
  • [23] OUTCOME OF LOWER-RISK PATIENTS WITH MYELODYSPLASTIC SYNDROMES WITHOUT 5Q DELETION AFTER FAILURE OF ERYTHROPOIESIS STIMULATING AGENTS
    Park, S.
    Hamel, J. F.
    Toma, A.
    Kelaidi, C.
    Thepot, S.
    Campelo Diez, M.
    Santini, V.
    Sekeres, M.
    Balleari, E.
    Kaivers, J.
    Goetze, K.
    Beyne-Rauzy, O.
    Stamatoullas, A.
    Kotsianidis, I.
    Komrokji, R.
    Steensma, D.
    Germing, U.
    Sanz, G.
    Dreyfus, F.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2017, 55 : S33 - S33
  • [24] Role of Erythropoiesis-Stimulating Agents (ESAs) in Supportive Care of Low-Risk Myelodysplastic Syndromes
    Cerchione, Claudio
    Alfinito, Fiorella
    Soriente, Ilaria
    D'Arco, Alfonso Maria
    Danise, Paolo
    Cerciello, Giuseppe
    Pane, Fabrizio
    Martinelli, Giovanni
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S324 - S325
  • [25] Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents
    Castelli, Roberto
    Schiavon, Riccardo
    Rossi, Valentina
    Deliliers, Giorgio Lambertenghi
    MEDICAL ONCOLOGY, 2018, 35 (05)
  • [26] A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes
    Madanat, Yazan F.
    Dezern, Amy E.
    LANCET HAEMATOLOGY, 2024, 11 (09): : e630 - e631
  • [27] Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents
    Roberto Castelli
    Riccardo Schiavon
    Valentina Rossi
    Giorgio Lambertenghi Deliliers
    Medical Oncology, 2018, 35
  • [28] p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes
    Frisan, Emilie
    Pawlikowska, Patrycja
    Pierre-Eugene, Cecile
    Viallon, Vivian
    Gibault, Laure
    Park, Sophie
    Mayeux, Patrick
    Dreyfus, Francois
    Porteu, Francoise
    Fontenay, Michaela
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (11): : 1964 - 1968
  • [29] Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents
    Park, Sophie
    Hamel, Jean-Francois
    Toma, Andrea
    Kelaidi, Charikleia
    Thepot, Sylvain
    Campelo, Maria Diez
    Santini, Valeria
    Sekeres, Mikkael A.
    Balleari, Enrico
    Kaivers, Jennifer
    Sapena, Rosa
    Goetze, Katharina
    Mueller-Thomas, Catharina
    Beyne-Rauzy, Odile
    Stamatoullas, Aspasia
    Kotsianidis, Ioannis
    Komrokji, Rami
    Steensma, David P.
    Fensterl, Jaime
    Roboz, Gail J.
    Bernal, Teresa
    Ramos, Fernando
    Calabuig, Marisa
    Guerci-Bresler, Agnes
    Bordessoule, Dominique
    Cony-Makhoul, Pascale
    Cheze, Stephane
    Wattel, Eric
    Rose, Christian
    Vey, Norbert
    Gioia, Daniela
    Ferrero, Dario
    Gaidano, Gianluca
    Cametti, Giovanni
    Pane, Fabrizio
    Sanna, Alessandro
    Germing, Ulrich
    Sanz, Guillermo F.
    Dreyfus, Francois
    Fenaux, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (14) : 1591 - +
  • [30] Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents
    Sibon, David
    Cannas, Giovanna
    Baracco, Fiorenza
    Prebet, Thomas
    Vey, Norbert
    Banos, Anne
    Besson, Caroline
    Corm, Selim
    Blanc, Michel
    Slama, Bohrane
    Perrier, Herve
    Fenaux, Pierre
    Wattel, Eric
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (05) : 619 - 625
12345